Flex Pharma Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Flex Pharma (FLKS) PT Lowered to $8 at Jefferies; HotShot Sales Impacted by Seasonality
May 4, 2017 8:19 AM EDTJefferies lowered its price target on Flex Pharma (NASDAQ: FLKS) to $8.00 (from $9.00) while maintaining a Buy rating.
Analyst Matthew Andrews notes HotShot sales were affected by seasonality as expected though there are signals that Q2 is off to a good start.
The firm cut FY 2017 EPS from ($1.90) to ($2.13)
... More